These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 24711548)
21. Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML. Pasic I; Da'na W; Lam W; Law A; Lipton JH; Viswabandya A; Kim DD; Thyagu S; Messner HA; Michelis FV Eur J Haematol; 2019 Apr; 102(4):368-374. PubMed ID: 30706524 [TBL] [Abstract][Full Text] [Related]
22. CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk. Park SH; Chi HS; Cho YU; Jang S; Park CJ Leuk Res; 2013 Nov; 37(11):1488-94. PubMed ID: 24054719 [TBL] [Abstract][Full Text] [Related]
23. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. Langer C; Marcucci G; Holland KB; Radmacher MD; Maharry K; Paschka P; Whitman SP; Mrózek K; Baldus CD; Vij R; Powell BL; Carroll AJ; Kolitz JE; Caligiuri MA; Larson RA; Bloomfield CD J Clin Oncol; 2009 Jul; 27(19):3198-204. PubMed ID: 19451432 [TBL] [Abstract][Full Text] [Related]
24. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735 [TBL] [Abstract][Full Text] [Related]
25. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. Wagner K; Damm F; Göhring G; Görlich K; Heuser M; Schäfer I; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar AA; Fiedler W; Kirchner HH; Brugger W; Zucknick M; Schlegelberger B; Heil G; Ganser A; Krauter J J Clin Oncol; 2010 May; 28(14):2356-64. PubMed ID: 20368538 [TBL] [Abstract][Full Text] [Related]
26. The value of molecular stratification for CEBPA(DM) and NPM1(MUT) FLT3(WT) genotypes in older patients with acute myeloid leukaemia. Dickson GJ; Bustraan S; Hills RK; Ali A; Goldstone AH; Burnett AK; Linch DC; Gale RE Br J Haematol; 2016 Feb; 172(4):573-80. PubMed ID: 26847745 [TBL] [Abstract][Full Text] [Related]
27. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H; N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602 [TBL] [Abstract][Full Text] [Related]
28. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448 [TBL] [Abstract][Full Text] [Related]
29. High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients. Tiribelli M; Raspadori D; Geromin A; Cavallin M; Sirianni S; Simeone E; Bocchia M; Fanin R; Damiani D Leuk Res; 2017 Jul; 58():31-38. PubMed ID: 28407515 [TBL] [Abstract][Full Text] [Related]
30. Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia. Wakita S; Yamaguchi H; Ueki T; Usuki K; Kurosawa S; Kobayashi Y; Kawata E; Tajika K; Gomi S; Koizumi M; Fujiwara Y; Yui S; Fukunaga K; Ryotokuji T; Hirakawa T; Arai K; Kitano T; Kosaka F; Tamai H; Nakayama K; Fukuda T; Inokuchi K Leukemia; 2016 Mar; 30(3):545-54. PubMed ID: 26488113 [TBL] [Abstract][Full Text] [Related]
31. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. Paschka P; Marcucci G; Ruppert AS; Whitman SP; Mrózek K; Maharry K; Langer C; Baldus CD; Zhao W; Powell BL; Baer MR; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD J Clin Oncol; 2008 Oct; 26(28):4595-602. PubMed ID: 18559874 [TBL] [Abstract][Full Text] [Related]
32. Prognostic implication of molecular aberrations in cytogenetically normal acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation. Liu YC; Hsiao HH; Lin PM; Yang WC; Chang CS; Liu TC; Hsu JF; Yang MY; Lin SF Genet Mol Res; 2013 Nov; 12(4):5414-23. PubMed ID: 24301914 [TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988 [TBL] [Abstract][Full Text] [Related]
35. ID1 expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia. Damm F; Wagner K; Görlich K; Morgan M; Thol F; Yun H; Delwel R; Valk PJM; Löwenberg B; Heuser M; Ganser A; Krauter J Br J Haematol; 2012 Jul; 158(2):208-215. PubMed ID: 22568493 [TBL] [Abstract][Full Text] [Related]
36. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656 [TBL] [Abstract][Full Text] [Related]
37. NPM1 gene mutation in Egyptian patients with cytogenetically normal acute myeloid leukemia. Sofan MA; Elmasry S; Salem DA; Bazid MM Clin Lab; 2014; 60(11):1813-22. PubMed ID: 25648021 [TBL] [Abstract][Full Text] [Related]
38. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing. Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340 [TBL] [Abstract][Full Text] [Related]
39. Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio. Versluis J; In 't Hout FE; Devillier R; van Putten WL; Manz MG; Vekemans MC; Legdeur MC; Passweg JR; Maertens J; Kuball J; Biemond BJ; Valk PJ; van der Reijden BA; Meloni G; Schouten HC; Vellenga E; Pabst T; Willemze R; Löwenberg B; Ossenkoppele G; Baron F; Huls G; Cornelissen JJ Leukemia; 2017 Jan; 31(1):26-33. PubMed ID: 27416910 [TBL] [Abstract][Full Text] [Related]
40. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia. Dalal BI; Mansoor S; Manna M; Pi S; Sauro GD; Hogge DE Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):274-9. PubMed ID: 22481022 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]